BioOutsource Ltd. has formed a partnership with Glythera Ltd., an emerging company specializing in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies. The move is intended to boost BioOutsource’s position in characterization of antibody-drug conjugates (ADCs). Dr. David Simpson, chief operating officer at Glythera, commented, “We are delighted to have the opportunity to work with BioOutsource on their ADC cha...